Showing results (351-360 of 782) with videos related to

Sort By:
Pageof 79
The Lancet. HIV|June 30, 2025
Safety, tolerability, and pharmacokinetics of an annual tenofovir alafenamide silicone subdermal implant in South African women: a two-part, randomised, placebo-controlled, double-blind, first-in-human, phase 1 trialTanuja N Gengiah, Lara Lewis, Ishana Harkoo, et al.
The Lancet. HIV|September 26, 2025
Understanding and managing disordered sleep in people with HIVLuxsena Sukumaran, Karine Scheuermaier, Caroline A Sabin, et al.
The Lancet. HIV|October 9, 2025
HIV-related outcomes among migrants living in Europe compared with the general population: a systematic review and meta-analysisFrancesco Vladimiro Segala, Francesco Di Gennaro, Luisa Frallonardo, et al.
The Lancet. HIV|September 15, 2025
Safety, tolerability, and immunogenicity of an adult-specific pneumococcal conjugate vaccine, V116, in people living with HIV (STRIDE-7): a two-part, parallel-group, randomised, active comparator-controlled, international, phase 3 trialJayani Pathirana, Moti Ramgopal, Charlotte Martin, et al.
The Lancet. HIV|September 14, 2025
Dynamic choice HIV prevention with long-acting injectable cabotegravir pre-exposure prophylaxis in east, central, southern, and west Africa: a cost-effectiveness modelling analysisAndrew N Phillips, Matthew D Hickey, Starley B Shade, et al.
The Lancet. HIV|June 27, 2025
Evaluation of antiretroviral regimen switching options in adults with HIV with sustained viral load non-suppression on dolutegravir, lamivudine, and tenofovir in eastern, central, southern, and western Africa: a modelling studyAndrew N Phillips, Loveleen Bansi-Matharu, Joep J van Oosterhout, et al.
The Lancet. HIV|June 9, 2025
Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trialPablo Ryan, José L Blanco, Mar Masia, et al.
The Lancet. HIV|March 30, 2025
HIV seropositivity and viral non-suppression in transgender, non-binary, and gender-diverse people in primary care receiving gender-affirming hormone therapy in the USA between 2013 and 2019 (LEGACY): an observational, longitudinal, cohort studySari L Reisner, David R Pletta, Kenneth H Mayer, et al.
The Lancet. HIV|March 29, 2025
Impact of an international HIV funding crisis on HIV infections and mortality in low-income and middle-income countries: a modelling studyDebra Ten Brink, Rowan Martin-Hughes, Anna L Bowring, et al.
The Lancet. HIV|April 3, 2025
Statin effects on the incidence of major non-cardiovascular disease events among a global cohort of people with HIV: a randomised controlled trialMarissa R Diggs, Triin Umbleja, Sara McCallum, et al.
Pageof 79